Development of Sustainable Curative and Preventive Tools for the Control of Zoonotic Diseases

45

Muhammad Ijaz Saleem[1,*], Asif Ali Butt[2], Ashar Mahfooz[1], Muhammad Saif ur Rehman [1], Faisal Ramzan[1], Fazeela Zaka[1], Syed Khalil ud Din Shah[3], Zeeshan Ahmad Bhutta[4], Ahmad Raza[1] and Muhammad umar Khan[3]

ABSTRACT

Zoonosis, the transmission of diseases between humans and animals, is categorized into endemic, epidemic, and emerging or re-emerging forms. The latter, exemplified by viruses like West Nile and MERS-CoV, presents a global challenge, causing one billion illnesses and millions of fatalities annually. Sixty percent of reported infectious ailments worldwide are zoonosis-related, with 75% of 30 novel human pathogens originating from animals in the last three decades. The Eastern Mediterranean Region is particularly vulnerable due to high population density, international trade, and frequent outbreaks, necessitating a strategic approach for early detection and management. Factors such as globalization and differing health system capabilities contribute to the genesis and transmission of zoonotic diseases, with disparities in surveillance and response capacities exacerbating outbreaks. The interconnectedness of the world raises concerns about the rapid international spread of these infections. Economic implications, including livestock losses and trade disruptions, further underscore the need for effective control strategies.

This chapter addresses public health challenges posed by emerging zoonotic infections in the Eastern Mediterranean Region, emphasizing rising risks, control challenges, and the importance of strategic approaches. Sustainable development of therapeutic and preventive tools is crucial for effective control. While advancements in diagnostics, treatments, vaccinations, and vector control have improved disease management, challenges like antibiotic resistance persist. Collaborative efforts, research, and innovation are essential for sustainable tools, ensuring effective zoonotic disease control with minimal environmental impact and long-term wellness for human and animal populations.

Key words: Zoonosis, Emerging Infections, Global Health, Eastern Mediterranean Region, Disease Control, Sustainable Development, One Health, Antibiotic Resistance, Collaboration, Public Health Challenges.

CITATION

Saleem MI, Butt AA, Mahfooz A, Rehman MS, Ramzan F, Zaka F, Shah SK, Bhutta ZA, Raza A and Khan MU, 2023. Development of Sustainable curative and preventive tools for the control of Zoonotic Diseases. In: Khan A, Abbas RZ, Hassan MF, Aguilar-Marcelino L, Saeed NM and Mohsin M (eds), Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan, Vol. I: 612-626. https://doi.org/10.47278/book.zoon/2023.045

CHAPTER HISTORY Received: 27-Jan-2023 Revised: 08-July-2023 Accepted: 04-Aug-2023

[1]University of Agriculture, Faisalabad, Pakistan
[2] Rapha International University (Faisalabad Campus),
[3]Livestock & Dairy Development Department, Baluchistan, 4 Chungbuk National University, Korea
***Corresponding author:** drijazsaleem@gmail.com

1. INTRODUCTION

The natural transmission of diseases and infections between humans and animals is referred to as zoonosis (Nii-Trebi 2017). There are three primary categories of zoonosis: a) endemic, which is widespread and affects both humans and animals; b) epidemic, which has sporadic temporal and spatial distribution; and c) emerging and re-emerging, which is either newly discovered in a population or has already existed but is now rapidly spreading both geographically and in terms of incidence. Examples of the latter include the West Nile virus, the Middle East respiratory syndrome coronavirus (MERS-CoV), SARS, the 2009 H1N1 pandemic, Yellow fever, Rift Valley fever, and SARS (Nii-Trebi 2017) AA.

Globally, zoonosis has been reported to be responsible for one billion diseases and millions of fatalities each year. About 60% of infectious ailments reported worldwide are zoonosis-related (Klous et al. 2016). 30 novel pathogens have been discovered in humans during the past three decades, 75% of which have animal origins (Gebreyes et al. 2014).

Due to a number of factors, the WHO has determined that the Eastern Mediterranean Region is extremely vulnerable to zoonotic diseases (WHO 2022). These involve the massive population density in the region, which causes close contact between humans and animals. Moreover, the region experiences a significant volume of international trade, including the cross-border movement of human beings and animals. Due to variables like foreign travel for tourism, business, or religious purposes, the area remains vulnerable to the danger of the rapid worldwide spread of illnesses with zoonotic origins due to its history of frequent outbreaks of emerging infectious diseases (Buliva et al. 2017). Significant risk factors in the genesis and transmission of such infectious diseases have been identified as globalization and differing health systems' abilities to identify epidemics early on.

The natural transmission of diseases and infections between humans and animals is referred to as zoonosis (Nii-Trebi 2017). There are three primary categories of zoonosis: a) endemic, which is widespread and affects both humans and animals; b) epidemic, which has sporadic temporal and spatial distribution; and c) emerging and re-emerging, which is either newly discovered in a population or has already existed but is now rapidly spreading both geographically and in terms of incidence. Examples of the latter include the West Nile virus, the Middle East respiratory syndrome coronavirus (MERS-CoV), SARS, the 2009 H1N1 pandemic, Yellow fever, Rift Valley fever, and SARS (Nii-Trebi 2017) AA.

Globally, zoonosis has been reported to be responsible for one billion diseases and millions of fatalities each year. About 60% of infectious ailments reported worldwide are zoonosis-related (Klous et al. 2016). 30 novel pathogens have been discovered in humans during the past three decades, 75% of which have animal origins (Gebreyes et al. 2014).

Due to a number of factors, the WHO has determined that the Eastern Mediterranean Region is extremely vulnerable to zoonotic diseases (WHO 2022 C). These involve the massive population density in the region, which causes close contact between humans and animals. Moreover, the region experiences a significant volume of international trade, including the cross-border movement of human beings and animals. Due to variables like foreign travel for tourism, business, or religious purposes, the area remains vulnerable to the danger of the rapid worldwide spread of illnesses with zoonotic origins due to its history of frequent outbreaks of emerging infectious diseases (Buliva et al. 2017). Significant risk factors in the genesis and transmission of such infectious diseases have been identified as globalization and differing health systems' abilities to identify epidemics early on.

At the animal-human interface, disparities in surveillance and response capacities between countries have typically made these outbreaks more severe (WHO 2022). The potential for rapid international spread of these zoonotic infections poses a significant concern to global health security, given the interconnectedness of the world and the proliferation of trade, including the movement of animals across borders (Buliva et al. 2017). Additionally, evolving zoonotic diseases have implications for the economy as they may result in a decline in opportunities for individuals to earn a livelihood owing to livestock losses, the loss of the animal trade, and disruptions to travel (Seimenis and Battelli 2018).

This chapter strives to address the serious public health issues brought on by the region's rising incidence of emerging zoonotic infections. It will particularly shed light on (a) the rising risks to public health posed by emerging zoonotic infections, (b) the challenges that need to be encountered in effectively controlling these infections, and (c) the importance of adopting a strategic approach focused on anticipating, detecting, and effectively managing these infections. As part of the overall control strategy, the chapter also emphasizes the necessity for the sustainable development of therapeutic and preventative tools (Seimenis and Battelli 2018).

2. INSIGHTS INTO THE REGION: A COMPREHENSIVE OVERVIEW

The WHO's East Mediterranean Region is still unsure of the full scope of the burden zoonotic diseases pose there. The region continues to encounter periodic and epidemic outbreaks of emerging zoonosis despite the prevalence of endemic zoonosis like brucellosis, anthrax, and rabies within the countries (Buliva et al. 2017). Numerous variables may be responsible for the widespread and repeated appearance of zoonotic diseases. These include the lack of efficient zoonosis management initiatives, the limited interaction between the human and animal health sectors, the lack of agreement on the roles and responsibilities of each sector, and the inadequate prioritization of zoonosis. These variables lead to both explosive outbreaks and continued difficulties in managing zoonotic diseases in the region. There are several disease amplifiers that may be directly responsible for the recent increase of emerging zoonosis in the region. In particular, in crisis-affected countries, they include factors like population shifts, fragmented health systems, insufficient response capabilities, inadequate laboratory diagnostic capabilities, and interruptions in standard public health services (Bloom et al. 2017). The growth and spread of developing zoonosis in the region have been significantly aided by these disease amplifiers.

3. CONNECTING THE DOTS: WHY ZOONOTIC DISEASES CANNOT BE IGNORED

The haphazard emergence and global transmission of novel pathogens, particularly viruses of animal origin, is a noteworthy finding about the trend of zoonotic diseases (Marano et al. 2007). Due to their propensity for epidemics, high case fatality rates, lack of particular treatments, and readily accessible vaccinations for the majority of these zoonotic diseases (apart from the yellow fever vaccine), these diseases constitute a serious threat to world health (Samad 2011). Emerging zoonosis in a single country has the potential to endanger the security of global health due to the world's growing interconnection.

However, zoonosis has an influence that goes beyond just being common. These diseases are significant owing to their prevalence as well as the morbidity, death, and heavy financial load they inflict on healthcare systems (Samad 2011). Furthermore, zoonosis have significant financial consequences for countries, leading to losses in the trade of animals, interruptions in travel, and reduced employment prospects for people owing to the loss of livestock (Buliva et al. 2017).

The waves of zoonotic ailments, diseases transmitted from animals to humans, reverberate far and wide, generating profound implications that can destabilize a nation's fiscal infrastructure (Hassan et al. 2011). These medical maladies, persistent and devastating, often precipitate not only a significant commercial contraction but also the erosion of trust amongst consumers and tourists. To underscore the fiscal fallout of such diseases, one only needs to cast their gaze back to the SARS outbreak of 2003. This medical catastrophe thrust the global economy into financial turmoil, with the total expenditures in response to the disease skyrocketing past USD 50 billion, attributable to mounting medical expenses and the unforeseen hibernation of the tourist industry.

Additionally, it behooves us to revisit the Rift Valley Fever (RVF) epidemic in Kenya. The tendrils of this disease infiltrated every household, compelling each one to grapple with an average financial setback of US$500 (WHO 2022 A). This unforeseen burden was principally linked to plunging productivity and the allocation of resources towards the containment of the disease. These instances, among others, underscore the profound and sizable monetary burden that zoonotic diseases can impose on nations. They elucidate the undeniable fact that the economics of disease are not confined merely to health care budgets but, rather, entwine themselves inextricably with the larger tapestry of a country's economy.

4. NAVIGATING COMPLEXITY: KEY CHALLENGES IN EFFECTIVE MANAGEMENT

Globalization has made it possible for the unparalleled movement of people, animals, and items to travel across international borders, which has helped zoonotic diseases spread throughout the world (Marano et al., 2007). Zoonosis affects a variety of industries, including trade, commerce, tourism, and consumer confidence. A substantial portion of zoonosis is trans-boundary diseases that may transcend borders from their place of origin. These diseases can, therefore, have devastating consequences for the economy (Hassan et al., 2011).

The Eastern Mediterranean Region of WHO's past instances have shown that the majority of zoonotic epidemics have happened in remote regions, making it difficult to reach these communities with public health services. Multiple factors have severely impeded the early identification and diagnosis of numerous diseases (WHO 2022). A few of these include the lack of suitable and secure mechanisms for sample shipment, the inadequate availability of on-site or in-country laboratory diagnostic facilities, the difficulty of deploying field investigation teams to remote areas, and the countries' inadequate ability to effectively plan, mobilize, and implement appropriate control measures in such configurations. It has also proven challenging to monitor the progress of control measures in geographically dispersed areas (WHO 2022 B).

It is essential to set up operational sub-national surveillance capabilities in order to identify and successfully combat these disease pitfalls (Van der Giessen et al. 2010). As a result, it is crucial to make investments in strengthening subnational outbreak surveillance and response capacities in countries that are consistently afflicted by these diseases. A significant proportion of the viral pathogens that cause emerging zoonotic diseases in humans have their origins in animals, especially wildlife or goods obtained from animals (Gebreyes et al. 2014). Understanding the epidemiology of these zoonotic diseases and creating viable strategies for control require knowledge of the existence of reservoirs of these diseases beyond human hosts.

It is frequently insufficient and results in a lack of transparency to promptly report new zoonotic diseases to WHO or other international organizations responsible for investigating and addressing potential hazards to global health security (OIE 2008). As a result, it might be difficult for these organizations to comprehend the epidemiology of the diseases, demonstrate the progression of diseases, and discover successful strategies for control in different settings. In some instances, medical authorities in certain countries deny the existence of human cases. This emphasizes the need for more global innovation and collaboration to overcome these issues (Berthe et al. 2018; World Bank 2010). In the section below, we go through a few of the key challenges in controlling zoonotic diseases (Fig 1).

4.1. LIMITED SURVEILLANCE SYSTEMS

The intricate battle against zoonotic diseases hinges significantly on the establishment and sustenance of steadfast monitoring apparatuses (Van der Giessen et al. 2010). The challenge, however, arises in many sectors, predominantly those grappling with a paucity of resources, as the initiation and consistent implementation of wide-ranging surveillance schemes prove taxing (Van der Giessen et al. 2010). The impediments, such as the constraints on resources, subpar infrastructure, and scarcity of skilled workforce, pose substantial hurdles to timely diagnosis and efficient reporting of zoonotic diseases. Augmentation of investment directed towards the reinforcement of surveillance frameworks, initiation of capacity amplification programs, and the generation of platforms for data interchange are all imperative elements in forging a robust response to the stipulations of this problem.

4.2. INTRICACIES OF TRANSMISSION DYNAMICS

The interplay in the transmission of zoonotic infections is inherently multifaceted, with a plethora of hosts, vectors, and environmentally dependent variables in play. The architecture of proficient control mechanisms hinges on the deciphering and comprehension of these intertwined pathways. However, conducting a meticulous dissection of the dynamics governing zoonotic disease transmission presents a formidable challenge, necessitating a confluence of expertise from epidemiology, ecology, and molecular biology. Confronting such formidable obstacles necessitates the synthesis of wisdom across various domains and fostering synergy among the stakeholders in the environmental, animal, and human health sectors (Coker et al. 2011). This collaborative momentum is vital for enhancing our understanding of the transmission mechanisms underlying zoonotic diseases and for fine-tuning the strategies aimed at their control.

4.3. GAPS IN VETERINARY AND PUBLIC HEALTH SYNERGIES

Effective coordination between the veterinary and public health sectors is crucial for the control of zoonotic diseases. However, poor communication and cooperation across these fields of study can prevent quick and well-planned responses to zoonotic disease outbreaks. The establishment of multidisciplinary training programs, the promotion of the One Health approach, and bridging the gap between veterinary and medical experts are vital when trying to solve this obstacle (Lee and Brumme 2013). These measures are critical for enhancing coordination between the veterinary and public health sectors in order to control zoonotic disease outbreaks successfully.

4.4. IMPACT OF ANTIMICROBIAL RESISTANCE ON GLOBAL HEALTH

Globally, antimicrobial resistance (AMR) has a significant impact on the management of zoonotic diseases. The improper use and overconsumption of antimicrobial drugs in both human and animal healthcare systems lead to the emergence and spread of resistant pathogens (Okocha et al. 2018). The limited supply of new antimicrobial drugs makes this problem severe. Antimicrobial stewardship programs must be put in place in order to combat AMR and maintain zoonotic diseases treatment options. Investing in research and development for new antimicrobial drugs and promoting the safe use of antibiotics are two additional important strategies for effectively combating AMR (FAO 2019 A).

4.5. THREAT OF EMERGING AND RE-EMERGING ZOONOTIC DISEASES

Public health systems remain confronted with challenges as a result of the emergence and reemergence of zoonotic diseases (Nii-Trebi 2017). The probability of zoonotic disease outbreaks is enhanced by factors including urbanization, deforestation, trade of wildlife, and climate change (Lindahl and Grace 2015). In order to manage these dynamic and evolving threats, prompt detection, early alert systems, and adaptive techniques are crucial. It is also possible to lessen the hazards brought on by developing zoonotic diseases by investing in research to comprehend the drivers of emergence and by putting preventive strategies in place, such as restrictions on the trade in wild animals and habitat preservation.

Significant obstacles must be overcome in order to effectively manage infectious diseases on a local, national, and international scale. An integrated strategy for controlling zoonotic diseases must address antibiotic resistance, improve coordination between the veterinary and public health sectors, strengthen surveillance systems, and effectively handle emerging challenges (Bidaisee and Macpherson 2014). We can overcome these obstacles and improve our capacity to prevent, detect, and control zoonotic diseases, thereby protecting public health and advancing the welfare of both humans and animals. We can do this by investing in research, innovation, capacity building, and promoting interdisciplinary collaboration (Zinsstag et al. 2011).

5. EVOLVING PARADIGMS IN ZOONOTIC DISEASE CONTROL

The sectors of animal and human health are not yet coherent in their approaches to the prevention and control of zoonotic diseases. For the prevention and management of newly developing zoonotic diseases, there are no initiatives either globally. The region hasn't undertaken any systematic attempts to design any strategy for the management and control of zoonotic diseases and related public health hazards because of a shortage of resources and satisfactory responses from policy makers.

6. PROMISING DEVELOPMENTS IN SUSTAINABLE CURATIVE AND PREVENTIVE TOOLS FOR THE MANAGEMENT OF ZOONOTIC DISEASES

For these diseases to be properly managed and controlled, the development of sustainable preventative and curative strategies seems crucial. This chapter examines how developments in medical science and technology have produced sustainable tools for the management of zoonotic diseases. It also covers the value of diagnostics, treatments, vaccinations, vector control methods, and the One Health strategy in preventing zoonotic diseases and maintaining long-term sustainability.

6.1. DIAGNOSTIC TOOLS

In order to effectively manage a medical issue, an accurate and prompt diagnosis is essential. Sustainable diagnostic methods provide quick and precise diagnosis of zoonotic diseases. By providing great sensitivity and specificity, molecular techniques like polymerase chain reaction (PCR) and next-generation sequencing have revolutionized diagnostics (Barzon, et al. 2011).

Due to their great sensitivity and specificity, molecular diagnostic methods are widely used to identify zoonotic diseases. Pathogen nucleic acids may be quickly and precisely identified using Polymerase Chain Reaction (PCR) and its variants, such as Reverse Transcription PCR (RT-qPCR) and Real-Time PCR (RT-PCR). These techniques are very useful for identifying infectious diseases in both human and animal specimens, including coronaviruses and avian influenza (Cruz et al. 2022).



Fig 1: Key Challenges in Effective Management of Zoonotic Diseases.

Serological investigations and point-of-care testing tools have also been crucial in providing rapid and precise diagnosis, especially in contexts with limited resources. Furthermore, novel zoonotic agents may now be found using strong metagenomic sequencing methods, facilitating early diagnosis and prevention. These sustainable diagnostic technologies provide effective disease surveillance, early diagnosis, and targeted therapy approaches (Cruz et al. 2022).

6.1.1. POINT OF CARE TESTING

Improvements in point-of-care testing have transformed zoonotic disease diagnostics, particularly in areas with limited resources. Rapid on-site testing is made possible by portable and user-friendly diagnostic tools, including handheld PCR instruments and lateral flow assays, which do not need a large laboratory setup (Velayudhan T and Hemant K 2022). These tools are crucial during epidemics because they allow for quick action and control efforts.

6.1.2. NEXT GENERATION SEQUENCING

Research and diagnosis of zoonotic diseases now have new directions thanks to next-generation sequencing technology. NGS makes it possible to thoroughly analyze pathogen genomes, making it easier to find genetic variants, virulence factors, and possible resistance to drugs. Furthermore, meta-genomic NGS has streamlined diagnostic procedures and improved our comprehension of complicated zoonotic diseases by enabling the identification of several pathogens in just one specimen (Lu X et al., 2022).

6.1.3. BIOSENSORS AND NANOTECHNOLOGY

The identification of zoonotic diseases has improved because of the incorporation of biosensors and nanotechnology in diagnostic tools. Biosensors have a high sensitivity and speed of detection for certain biomolecules, such as antigens or nucleic acids. Assays using nanoparticles provide better target selectivity and better detection capabilities (Ramakrishnan SG et al. 2021). The development of portable, quick, and affordable diagnostic tools for zoonotic diseases has a lot of promise using these technologies.

6.1.4. SEROLOGICAL ASSAYS

The diagnosis of zoonotic diseases, particularly those brought on by bacteria and certain parasites, still relies heavily on serological testing. Rapid Diagnostic Tests (RDTs) and enzyme-linked immunosorbent assays (ELISAs) are often used to identify particular antibodies in the blood that signify recent or ongoing diseases (Kumar et al. 2018). Serological testing is essential for tracking the incidence of diseases in animal populations, locating possible reservoirs, and determining the threat of human transmission.

The veterinary industry has recently experienced notable improvements in diagnostic methods for the control of zoonotic infections. Molecular approaches, serological tests, point-of-care testing, next-generation sequencing, and the use of biosensors and nanotechnology have all made it possible to better diagnose, treat, and prevent diseases (Velayudhan T and Hemant K, 2022). For successful zoonotic disease management, prompt interventions, and the reduction of public health hazards, sustainable diagnostic technologies must be developed and immediately implemented. Veterinary field stays at the forefront of using cutting-edge methods to fight zoonotic diseases and guarantee a better and healthier future for humans as well as animals as technology advances.

6.2. CUTTING-EDGE THERAPEUTIC INTERVENTIONS FOR IMPROVED OUTCOMES

For the treatment of zoonotic diseases in both humans and animals, the development of sustainable therapeutic interventions is essential. Drugs that are antiviral, antibiotic, anti-parasitic, and antifungal have proven crucial in the fight against zoonotic diseases. The emergence of antibiotic resistance, however, poses a severe danger to the long-term sustainability of these drugs (Okocha et al. 2018).

Responsible use of antibiotics, the creation of alternative therapy decisions, and the implementation of antimicrobial stewardship programs are all examples of sustainable therapeutic techniques. These strategies also reduce the emergence of resistance. The combination of conventional drugs and natural remedies can also support sustainable treatment strategies. This section examines contemporary advancements in veterinary medicine, focusing on novel treatment methods that have fundamentally changed the practice of veterinary medicine.

6.2.1. IMMUNOTHERAPY

In animals, immunotherapy has shown significant potential for treating a variety of malignancies as well as immune-mediated diseases. It is possible to boost the immune system so that it targets and destroys aberrant cells through the use of therapeutic vaccinations and immune modulators. This may lead to better results for cancer patients (Grosenbaugh et al. 2011).

6.2.2. REGENERATIVE MEDICINES

The discipline of veterinary medicine known as regenerative medicine has recently emerged as a potentially fruitful area of study. This subspecialty of veterinary medicine focuses on leveraging the body's natural healing mechanisms in order to repair and regenerate damaged tissues and organs. For instance, therapy with stem cells has shown substantial promise in treating orthopedic problems and boosting tissue regeneration in animal models (Black et al 2007).

6.2.3. PERSONALIZED MEDICINES

The use of personalized medicine in veterinary practice has been made possible by recent developments in molecular diagnostics and genetic testing. It is possible to achieve greater precision and efficacy in therapeutic interventions by customizing therapies according to the genetic make-up of particular individuals (Mellersh 2015).

6.2.4. TARGETED DRUG THERAPIES

Animal disease treatments that use targeted drug therapies, which explicitly target certain biochemical pathways, have had a tremendous amount of success. In comparison to conventional treatments, these therapies are more beneficial and less harmful (London et al. 2009).

With the development of cutting-edge therapeutic interventions, veterinary medicine has significantly advanced, providing hope and improved outcomes for animals suffering from various diseases. These advancements, which range from immunotherapy and regenerative medicine to personalized medicine and less invasive treatments, are a reflection of the veterinary profession's commitment to provide the best possible treatment for animals (Grosenbaugh et al. 2011).

6.3. VACCINES

The prevention of zoonotic diseases continues to be accomplished with great success through vaccination. The development of sustainable vaccines is essential for preventing the spread of zoonotic diseases. These sustainable vaccines are distinguished notably for their great effectiveness, safety, and accessibility. To fight zoonotic diseases, several vaccination platforms have been used over the years. Live attenuated vaccines, inactivated vaccines, subunit vaccines, and vector-based vaccines are only a few examples of the wide variety that these platforms cover. Additionally, techniques for manufacturing vaccines sustainably have emerged, taking into account important factors including thermo stability, cold chain logistics, and cost-effective production. These factors are essential for ensuring that vaccines are widely accessible and distributed fairly, reaching people in need throughout the globe (Bird and Nichol 2012).

6.3.1. INACTIVATED VACCINES

The pathogens in inactivated vaccinations commonly referred to as killed vaccines, have been rendered non-viable by chemical or physical processes. As a result of the viruses' inability to reproduce and spread diseases, these vaccinations are regarded as safe. However, adjuvants may be necessary to boost the immune response in order for them to be effective. The use of inactivated vaccinations against zoonotic diseases, including rabies and certain strains of avian influenza, has proved beneficial (Hemachudha et al. 2018).

6.3.2. SUBUNIT VACCINES

In contrast to entire microorganisms, subunit vaccines use particular antigenic parts of the pathogen. These vaccinations are simple to make using recombinant DNA technology and are safe. They reduce the possibility of negative effects by inducing focused immune responses. Subunit vaccines have shown potential in the fight against zoonotic diseases, including hepatitis B and other diseases transmitted by ticks (Sureau 2019).

6.3.3. LIVE ATTENUATED VACCINES

Live attenuated vaccines include microorganisms that are less virulent than wild-type strains but nonetheless capable of replication. These vaccinations often cause strong immune reactions that endure for a long time and provide durable protection. A rigorous selection of strains and safety testing are necessary due to the possibility of reversion to virulence. Measles, mumps, and certain influenza strains are examples of zoonotic diseases that have been effectively prevented by live attenuated vaccinations (WHO 2022).

6.3.4. VECTOR VACCINES

In order to deliver particular pathogen antigens to the immune system, vector vaccines employ non-pathogenic viruses or bacteria as carriers. These transporters, sometimes referred to as vectors, strongly incite immunological reactions against the transmitted antigens. When combating zoonotic diseases with intricate life cycles, vector vaccines are very helpful. They have shown potential in the fight against diseases, including West Nile virus infections and Lyme disease (van Eijk et al. 2019).

The veterinary field has made incredible strides in creating a variety of vaccinations for zoonotic disease prevention. In terms of security, effectiveness, and focused immune responses, inactivated vaccines, subunit vaccines, live attenuated vaccines, and vector vaccines each have specific benefits (Kaba et al., 2009). The strategic use of various vaccine types becomes essential in protecting both human and animal populations from the devastating effects of zoonotic diseases as zoonotic risks continue to develop (Haas and Petrovsky 2017). The veterinary field continues to play a crucial role in mitigating zoonosis and advancing the security of global health by leveraging the strength of contemporary vaccination technology and upholding a One Health approach.

6.4. VECTOR CONTROL STRATEGIES

Public health is severely compromised by vector-borne diseases that are transmitted through the bites of infected arthropods, such as mosquitoes, ticks, and fleas (WHO 2019). Zoonotic diseases often depend on vectors like mosquitoes, ticks, and fleas for transmission. In order to stop the cycle of disease transmission, it is essential to implement sustainable vector control techniques. It has been proven successful to adopt integrated vector management strategies, which combine the use of insecticides, biological control agents, and genetic modification strategies (Welburn S et al. 2009). In order to reduce vector populations and minimize ecological impact, sustainable vector control measures prioritize environmental management, habitat modification, and community involvement. Long-term sustainability in vector control efforts can be attained through the adoption of integrated strategies that take ecological and social concerns into consideration.

6.4.1. INTEGRATED VECTOR MANAGEMENT

As we delve into the complex realm of vector control, it becomes clear that a multifaceted, interdisciplinary framework, known as Integrated Vector Management (IVM), is the key to success. Uniting a myriad of strategic mechanisms, IVM forms a harmonious orchestra of interventions designed to bring about the reduction of vector populations and thereby, the containment of zoonotic infections.

Consider IVM as a vibrant mosaic. Each piece – or intervention – plays a vital role, and together they form a coherent whole. The centrality of community engagement cannot be overstressed; it is in the social fabric of our societies that we discover the allies needed to halt the growth of vector populations.

Likewise, education serves as an empowering tool, fostering understanding and fueling a proactive stance against vectors. A well-informed society becomes the most potent defense, able to recognize and react to the threats posed by vectors.

Then, there are the carefully calculated applications of pesticides - a tactical component requiring precision. These chemicals, deployed judiciously, act as powerful adversaries to vectors. Not to be overshadowed is the employment of biological control strategies, where the canvas of Mother Nature herself is used to counteract vector proliferation. This approach harnesses the inherent balance of nature to keep vector populations in check.

Lastly, let's draw attention to environmental management. This aspect points to the optimization of our surrounding environment to inhibit vector growth and spread. It is a fascinating piece of the puzzle, bridging the gap between humans, their behavior, and their habitat (WHO 2019).

Hence, Integrated Vector Management embodies a synergistic approach, a chorus of interventions singing the same tune: Decrease vector populations, curtail the spread of zoonotic infections. It is a song of unity, resilience, and ultimately, survival.

6.4.2. BIOLOGICAL CONTROL

Utilizing natural predators, parasites, or pathogens to manage vector populations is known as biological control. For instance, adding fish that feed on mosquito larvae to bodies of water helps prevent mosquito reproduction. Similar to this, controlling tick and flea populations may be accomplished by using parasitoids or entomo-pathogenic fungi (Lacey et al. 2015).

6.4.3. ENVIRONMENTAL MODIFICATION

Controlling vectors requires significant modifications to the environment. Simple actions like eliminating standing water, reducing possible breeding grounds, and enhancing cleanliness may drastically reduce vector populations. Additionally, reducing human-vector interaction and disease transmission may be assisted through habitat alteration and land-use planning (Qualls et al. 2018).



Fig. 2: Components of the one health approach: interdependencies between human, animal, and environmental health.

6.4.4. INSECTICIDE-BASED CONTROL

As a method for managing vectors, insecticide-based control is still crucial. Insecticide-treated bed nets and residual spraying may both help reduce vector populations and halt the spread of diseases. The rise of pesticide resistance, however, emphasizes the necessity for responsible and sustainable use of these agents (Pennetier et al. 2013).

6.4.5. GENETIC CONTROL

With the swift evolution in the sphere of genetic tech wizardry, we are witnessing the dawn of imaginative, avant-garde strategies for the absolute eradication of disease carriers, or as they are scientifically known, vectors. Consider this illustrative scenario: vectors that have undergone a genetic transformation, effectively reducing their capability to transmit diseases - a phenomenon coined as "vector competence". Or, an equally captivating case - the infusion of sterile vectors, essentially creating a population of vectors that cannot reproduce. What fundamental principle underlies these incredible feats of genetic engineering? It's relatively straightforward - the overall reduction of vector populations (Deredec et al. 2008).

Strategies aimed at controlling vectors are an essential component of programs designed to avoid zoonosis. The competence of the veterinary profession in understanding the biology of vectors and the transmission of diseases is essential for the implementation of comprehensive and sustainable ways to decrease the number of vector populations and restrict the transmission of zoonotic diseases (Qualls et al. 2018). Integrated Vector Management (IVM), which offers a complete framework for coordinating many control techniques, is one example of a new strategy. Other creative approaches, including biological control and genetic control, provide potential avenues for the future of vector management.

6.5. THE ONE HEALTH APPROACH

The One Health strategy recognizes the complex interdependencies between human, animal, and environmental health (Fig 2) in the struggle against zoonotic diseases (Brückner 2009; FAO 2019). Effective cooperation between experts in human health, veterinary medicine, ecology, and policymakers is necessary to ensure the sustainable management of zoonotic diseases. In order to effectively combat zoonotic threats, the One Health strategy promotes multidisciplinary research, makes data exchange easy, and provides policy frameworks. It emphasizes the necessity of responsible animal husbandry, wildlife protection, and sustainable land use practices to prevent and control zoonotic diseases at their source (Zinsstag et al. 2011).

7. CONCLUSION

For effective zoonotic disease control and management, it is crucial to develop sustainable curative and preventive methods. Significant improvements in disease prevention and control have resulted from developments in diagnostics, treatments, vaccinations, vector control strategies, and the adoption of the One Health strategy. Nevertheless, problems including antibiotic resistance, evolving zoonotic challenges, and a lack of resources persist. Strengthening the development and use of sustainable tools requires continued research, innovation, and collaboration across borders. We can successfully manage zoonotic diseases while minimizing adverse environmental impacts, sustaining treatment options, and ensuring the long-term wellness and health of both human and animal populations by investing in sustainable measures.

REFERENCES

Barzon L et al., 2011. Applications of next-generation sequencing technologies to diagnostic virology. International journal of molecular sciences 1211: 7861-7884.

Berthe FCJ et al., 2018 Operational framework for strengthening human, animal and environmental public health systems at their interface English. Washington, D.C.: World Bank Group

Bidaisee S et al., 2014. Zoonoses and one health: a review of the literature. Journal of parasitology research 2014.

Bird BH et al., 2012. Breaking the chain: Rift Valley fever virus control via livestock vaccination. Current Opinion in Virology 23: 315–323.

Black LL et al. 2007. Effect of Adipose-Derived Mesenchymal Stem and Regenerative Cells on Lameness in Dogs with Chronic Osteoarthritis of the Coxofemoral Joints: A Randomized, Double-Blinded, Multicenter, Controlled Trial. Veterinary Therapeutics 84: 272-284.

Bloom DE et al., 2017. Emerging infectious diseases: A proactive approach. Proceedings of the National Academy of Sciences 11416: 4055-4059.
Brückner G, 2009. The role of the World Organisation for Animal Health OIE to facilitate the international trade in animals and animal products. Onderstepoort Journal of Veterinary Research 761: 141–146.
Buliva E et al., 2017. Emerging and Reemerging Diseases in the World Health Organization WHO Eastern Mediterranean Region-Progress, Challenges, and WHO Initiatives. Frontiers in public health 5: 276.
Coker R et al., 2011. Towards a conceptual framework to support one-health research for policy on emerging zoonoses. The Lancet infectious diseases 114: 326-331.
Cruz N et al., 2022. The age of next-generation therapeutic-microbe discovery: exploiting microbe-microbe and host-microbe interactions for disease prevention. Infection and Immunity 905: e00589-21.
Deredec A et al., 2008. The Population Genetics of Using Homing Endonuclease Genes in Vector and Pest Management. Genetics 1794: 2013-2026.
FAO, 2019. Aquaculture development. 8. Recommendations for prudent and responsible use of veterinary medicines in aquaculture. FAO Technical Guidelines for Responsible Fisheries, FAO.
FAO, 2019 (A). Our priorities – The strategic objectives of FAO. Rome, FAO.
Gebreyes WA et al., 2014. The global one health paradigm: challenges and opportunities for tackling infectious diseases at the human, animal, and environment interface in low-resource settings. PLoS neglected tropical diseases 811: e3257.
Grosenbaugh DA et al., 2011. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American Journal of Veterinary Research 7212: 1631-1638.
Haas RM et al., 2017. Tick-Borne Encephalitis Virus: A Review of an Emerging Zoonosis. Journal of General Virology 983: 533-548.
Hassan OA et al., 2011. The 2007 rift valley fever outbreak in Sudan. PLOS Neglected Tropical Diseases 59: e1229.
Hemachudha T et al., 2018. Rabies: Challenges and Solutions. In: Barrett ADT, Stanberry LR, editors. Vaccines for Biodefense and Emerging and Neglected Diseases: Academic Press; pp: 781-808.
Kaba SA et al. 2009. A Nonadjuvanted Pneumococcal Whole-Cell Vaccine: Protective Immunogenicity and Dose Response. Journal of Infectious Diseases 2002: 212-220.
Klous G, 2016. Human–livestock contacts and their relationship to transmission of zoonotic pathogens, a systematic review of literature. One Health 2: 65-76.
Kumar S, 2018. Quality control of vaccines-A journey from classical approach to 3Rs. Microbiology: Current Research 23: 45-61.
Lacey LA, 2015. Insect pathogens as biological control agents: Back to the future. Journal of Invertebrate Pathology 132: 1-41.
Lee K, 2013. Operationalizing the One Health approach: The global governance challenges. Health Policy and Planning 287: 778–785.
Lindahl JF, 2015. The consequences of human actions on risks for infectious diseases: a review. Infection ecology & epidemiology 51: 30048.
London CA et al., 2009. Multi-Center, Placebo-Controlled, Double-Blind, Randomized Study of Oral Toceranib Phosphate SU11654, a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent Either Local or Distant Mast Cell Tumor Following Surgical Excision. Clinical Cancer Research 1511: 3856-3865.
Lu X et al., 2022. Co-Localization of Sampling and Sequencing for Zoonotic Pathogen Identification in the Field Monitoring Using Mobile Laboratories. China CDC weekly 4(12): 259–263.
Marano N, 2007. Impact of globalization and animal trade on infectious disease ecology. Emerging Infectious Diseases 1312: 1807.
Mellersh CS, 2015. Gene Mutation Testing in Clinically Affected and At-Risk Dogs. Journal of Veterinary Internal Medicine 291: 38-41.
Nii-Trebi NI, 2017. Emerging and neglected infectious diseases: Insights, advances, and challenges. BioMed Research International 2017: 1–15.
OIE, 2008. Contributing to One World, One Health: A strategic framework for reducing risk of infectious diseases at the animal-human-ecosystem interface. FAO/OIE/WHO/UNICEF/UNSIC/World Bank

Okocha RC, 2018. Food safety impacts of antimicrobial use and their residues in aquaculture. Public Health Reviews 39: 21.
Pennetier C et al., 2013. Efficacy of Olyset® Plus, a New Long-Lasting Insecticidal Net Incorporating Permethrin and Piperonyl-butoxide against Multi-Resistant Malaria Vectors. PLoS ONE 810: e75134.
Qualls WA, 2018. Biting and resting behavior of Culex mosquitoes in relation to thermal and spatial gradients in a subtropical urban environment. Journal of Medical Entomology 556: 1454-1463.
Ramakrishnan SG et al., 2021. Nanotechnology based solutions to combat zoonotic viruses with special attention to SARS, MERS, and COVID 19: Detection, protection and medication. Microbial pathogenesis 159: 105133.
Samad MA, 2011. Public health threat caused by zoonotic diseases in Bangladesh. Bangladesh Journal of Veterinary Medicine 92: 95-120.
Seimenis A, 2018. Main challenges in the control of zoonoses and related foodborne diseases in the South Mediterranean and Middle East region. Veterinaria italiana 542: 97-106.
Sureau C, 2019. The Hepatitis B Virus and Anti-HBc: Unanswered Questions and New Challenges. Journal of Hepatology 712: 200-202.
Van der Giessen JWB et al., 2010. Emerging zoonoses: early warning and surveillance in the Netherlands. RIVM rapport 330214002.
van Eijk JJJ et al., 2019. Review of Immune Responses to Modified Vaccinia Virus Ankara: Implications for Vaccine Development. Journal of Virology 9320: e00724-19.
Velayudhan T and Hemant K, 2022. Point-of-care testing in companion and food animal disease diagnostics. Frontiers in Veterinary Science 9.
Welburn S et al., 2009. Controlling sleeping sickness– A review. Parasitology 13614: 1943–1949.
World Bank, 2010. People, pathogens and our planet, volume 1: Towards a One Health approach for controlling zoonotic diseases. Washington, DC: World Bank Group.
World Health Organization WHO, 2019. Handbook for Integrated Vector Management. [Online].
World Health Organization WHO, 2022 (A). Vaccines and vaccination against yellow fever: WHO position paper, June 2013-recommendations. Vaccine, 4015, 2122-2145.
World Health Organization WHO, 2022 (B). WHO Global Health Emergency Appeal 2022 regional summary: Eastern Mediterranean region.
World Health Organization WHO, 2022 (C). Zoonotic disease: emerging public health threats in the Region.
Zinsstag J et al., 2011. From “one medicine” to “one health” and systemic approaches to health and wellbeing. Preventive Veterinary Medicine 1013-4: 148–156.